Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study
试验速览
- 阶段
- 4 期
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Weight loss
研究概览
简要总结
The purpose of this study is to determine whether lorcaserin is effective for weight reduction in patients with weight gain as a result of antipsychotic medications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Lorcaserin with intensive diet counseling
Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
干预措施: lorcaserin (Drug)
Lorcaserin with intensive diet counseling
Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
干预措施: Intensive dietary counseling (Behavioral)
结局指标
主要结局
Weight loss
时间窗: initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study
The primary objective of this study is to evaluate the effectiveness of lorcaserin for weight loss management in patients on an antipsychotic agent. Will monitor the weight of the patient for evaluation.
次要结局
- Evaluation of cravings(initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study)
- Monitoring of mood(At initial visit, then at week 4 and week 12 of the study)
- Evaluation of systolic blood pressure(initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study)
- Evaluation of diastolic blood pressure(initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study)
- Evaluation of pulse(initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study)
- Evaluation of body-mass index (BMI)(initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study)
- Evaluation of waist circumference(initial visit with provider, then at weeks 1, 2, 4, 8, 12, and 16 of the study)
- Evaluation of glucose control(At initial visit and at week 12 of the study)
- Evaluation of cholesterol control(At initial visit and at week 12 of the study)
- Evaluation of electrolytes(At initial visit and at week 12 of the study)
- Evaluation of liver(At initial visit and at week 12 of the study)
- Evaluation of blood count(At initial visit and at week 12 of the study)
研究者
Charles Nguyen
Psychiatrist
Southern California Institute for Research and Education